These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28262545)

  • 21. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.
    Ooi EM; Barrett PH; Watts GF
    Int J Cardiol; 2013 Oct; 168(3):1811-8. PubMed ID: 23907036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
    Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE
    Gu L; Gong Y; Zhao C; Wang Y; Tian Q; Lei G; Liang Y; Zhao W; Tan S
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31731717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
    J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
    Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Sanna C; Stéphenne X; Revencu N; Smets F; Sassolas A; Di Filippo M; Descamps OS; Sokal EM
    Atherosclerosis; 2016 Apr; 247():97-104. PubMed ID: 26894473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia.
    Viigimaa M; Heinsar S; Lovic D; Katsimardou A; Piperidou A; Duishvili D
    Curr Pharm Des; 2018; 24(31):3599-3604. PubMed ID: 30306860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of two familial hypercholesterolemia patient-specific induced pluripotent stem cell lines harboring heterozygous mutations in the LDLR gene.
    Gao J; Li J; Xu L; Yan CD; Knowles JW; Wu JC
    Stem Cell Res; 2024 Aug; 78():103463. PubMed ID: 38852422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia.
    Darabi M; Lhomme M; Ponnaiah M; Pučić-Baković M; Guillas I; Frisdal E; Bittar R; Croyal M; Matheron-Duriez L; Poupel L; Bonnefont-Rousselot D; Frere C; Varret M; Krempf M; Cariou B; Lauc G; Guerin M; Carrie A; Bruckert E; Giral P; Le Goff W; Kontush A
    J Clin Lipidol; 2023; 17(5):643-658. PubMed ID: 37550151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
    Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
    J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
    [No Abstract]   [Full Text] [Related]  

  • 37. New Approaches in Detection and Treatment of Familial Hypercholesterolemia.
    Hartgers ML; Ray KK; Hovingh GK
    Curr Cardiol Rep; 2015 Dec; 17(12):109. PubMed ID: 26482752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The relationship between genotype of familial hypercholesterolemia and the efficacy of PCSK9 inhibitors].
    Zhang H; Ye PC; Wang XM; Wu X; Peng J; Wang SL; Lin J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Jun; 49(6):572-579. PubMed ID: 34126724
    [No Abstract]   [Full Text] [Related]  

  • 40. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
    Abifadel M; Rabès JP; Jambart S; Halaby G; Gannagé-Yared MH; Sarkis A; Beaino G; Varret M; Salem N; Corbani S; Aydénian H; Junien C; Munnich A; Boileau C
    Hum Mutat; 2009 Jul; 30(7):E682-91. PubMed ID: 19319977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.